Phase 3 N=1,636 Ocular Hypertension Treatment Study (OHTS)
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4,812 A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
N/A N=102 Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intra- Examiner Agreement in Angle Width by Goniometric Lens — 0.88 Kappa statistics
N/A N=854 Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 19.0; -4.0; 20.0; -5.0 Millimeters of Mercury (mmHg)
Phase 4 N=263 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye — 16.5; 16.7; 15.7; 16.1 Millimeters of Mercury (mmHg)
N/A N=358 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Right Eye — -4.5 mmHg
Phase 4 N=87 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Phase 3 N=466 A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye — 34.3; 39.1 Percentage of Patients
Phase 4 N=111 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
Glaucoma
Primary: Mean Intraocular Pressure (IOP) at 9 AM — 16.3; 18.1 millimeters mercury (mmHg)
Phase 4 N=376 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 25.4; -6.3 Millimeters of Mercury (mmHg)
Phase 4 N=800 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale — 40; 49; 20; 71 Participants
N/A N=10,337 A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 20.0; -4.0; 20.0; -4.0 Millimeters of Mercury (mmHg)
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
N/A N=1,553 A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.18; 16.11 mmHg
Phase 4 N=35 Circadian Ocular Perfusion Pressure and Ocular Blood Flow
Glaucoma
Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)
Phase 2 N=172 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Ocular Hypertension · Glaucoma
Primary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.350; 25.318; 25.341; 24.650 Millimeters of Mercury (mmHg)
N/A N=2,580 A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 20.51; 20.65 Millimeters of Mercury (mmHg)
Phase 3 N=237 Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Decrease From Baseline in Intraocular Pressure — 2.9; 1.6 mmHg
Phase 2 N=112 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP) — 24.54; 24.38; 24.29; -6.79 Millimeters of Mercury (mmHg)
Phase 2 N=47 Safety and Efficacy of a Drug Delivery System in Glaucoma
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
N/A N=419 A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 21.23; 21.38 Millimeters of Mercury (mmHg)
N/A N=235 Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open-angle Glaucoma · Ocular Hypertension
Primary: The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4 — 25.20; 24.87; -9.38; -8.93 Millimeters of…
Phase 4 N=86 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Nocturnal IOP at Week 4 — 24.2; 23.6; 18.6; 18.9 mmHg
Phase 3 N=193 Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Decrease From Baseline in Intraocular Pressure at Week 8 Predose — 3.5; 1.6 mmHg
Phase 3 N=148 DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Phase 3 N=192 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12 — 24.62; 25.12; -10.03; -9.18 mmHg
N/A N=933 Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 22.04; 22.07 mm Hg
Phase 3 N=495 To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Change in Intra-ocular Pressure — -4.25; -3.80; -4.22; -4.00 mmHG
Phase 3 N=185 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test — 25.42; 24.43; -10.45; -8.28 Millimeters of Mercury (mmHg)
Phase 2 N=109 Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Time-Matched Intraocular Pressure (IOP) in the Study Eye — 26.57; 25.14; 24.48; 25.14 Millimeters of Mercury (mmHg)